Blog

Tech Nation Visa: the gateway to world-leading UK tech jobs

At BenevolentAI we are always on the lookout for exceptional people to join us on our mission to re-engineer drug discovery and deliver life changing medicines to patients.


Our teams are curious, open to new ideas and passionate about making a positive impact on the world. At BenevolentAI we value different experiences, skills, and backgrounds and believe a diverse and inclusive environment is necessary to push technological and scientific boundaries. 

A globally diverse perspective is important, which is why we encourage the best tech talent from around the world to join us. As such, we want to draw attention to the Tech Nation Visa, also known as the Global Talent Visa in digital technology, which is a great initiative that enables the brightest international talent to live and work in the UK. 

Tech Nation, a close partner of BenevolentAI, has been designated by the Home Office to endorse applications for this Visa.  The application process is based on your unique background, skills, and achievements and there are two pathways to apply, depending on your experience:  Exceptional Talent and Exceptional Promise. The Tech Nation visa is highly flexible, not tied to a specific job, company or location. Applicants can have experience in any tech subsector and either business or technical backgrounds. It is granted for up to 5 years, with the ability to extend as many times as required. The Tech Nation Visa can also lead to permanent residency here in the UK.

Whether you have an established career in tech, or are finding your feet, the UK’s flourishing tech scene provides rich opportunities for entrepreneurs to set up or scale a business, or find employment at an existing firm. 52% of those endorsed last year by Tech Nation are now employed at leading UK tech firms, helping to fill existing talent gaps, while 28% have launched their own businesses. 

At BenevolentAI you have the chance to work alongside our world-leading experts, building tech which has real impact and contributes directly to our mission to improve patients’ lives. If you are a talented and creative individual interested in joining us on this mission, this could be your answer. 

Start building your career today, and find out more on the Tech Nation Visa guide here. 

Best of luck in your application.

The BenevolentAI Team


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021